WOBURN, MA — Vaxess Technologies, Inc., a biotech company developing a novel microarray patch technology to transform home delivery of therapies, has received an additional $9 million in funding. Investors included RA Capital Management and Engine Ventures. Vaxess will use its funding to continue to advance its work in GLP-1, and expand manufacturing capabilities to support the lead program and new partnerships for additional therapeutics.
“From GLP-1 to insulin, doctors prescribe numerous drugs that require people to self-inject, which can cause physical and psychological discomfort,” said Rachel Sha, CEO of Vaxess. “Vaxess’s microarray patch is the future of drug delivery. In the coming years, instead of having to perform an uncomfortable self-injection for a range of conditions, people will be able to simply apply a band-aid-like patch for a few minutes. Additionally, for therapies that require being refrigerated during shipment and storage, this room temperature stable patch eliminates the burden and cost associated with cold chain.”
Over the last year, Vaxess demonstrated ability to effectively deliver the clinical dose of GLP-1 RA, semaglutide leveraging the Vaxess platform and process. The company has evaluated patch delivered semaglutide versus subcutaneous injection of semaglutide in minipigs and rodents, showing comparable bioavailability.
Additionally, in 2024 Vaxess signed an agreement with a leading biopharma company to collaborate on delivering diabetes and obesity therapeutics. Over the course of the partnership, Vaxess will work with them to demonstrate the pharmacokinetic properties of administering their drug via Vaxess’s patch and evaluate how these properties compare to the typical method of subcutaneous injection in a swine model.
Leave a Reply